Sebelipase Alfa
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Sebelipase Alfa: Scheie syndrome
One-Sentence Summary
Sebelipase alfa (KANUMA) is a recombinant lysosomal acid lipase enzyme replacement therapy. The TxGNN model predicts it may be relevant to Scheie syndrome (Scheie syndrome), with a score of 0.9980. However, no clinical trials and no publications directly study this use, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Scheie syndrome |
| TxGNN Prediction Score | 0.9980 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Based on its known drug class, sebelipase alfa is an enzyme replacement therapy that supplies lysosomal acid lipase, which breaks down cholesteryl esters and triglycerides.
Scheie syndrome (attenuated mucopolysaccharidosis type I) is caused by a deficiency of a different enzyme, alpha-L-iduronidase, whose substrates are glycosaminoglycans. Sebelipase alfa does not replace this enzyme and does not act on these substrates. The only connection is the general concept of lysosomal enzyme replacement. The high model score is therefore not supported by a specific mechanism, and this prediction should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02469596 | KANUMA | Not specified | Not specified |
Safety Considerations
Please refer to the package insert for safety information.
No drug interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications, and there is no plausible mechanistic link between lysosomal acid lipase replacement and alpha-L-iduronidase deficiency. Evidence is at the model-prediction level only (L5).
To proceed, the following is needed:
- Preclinical data showing that sebelipase alfa has any activity in Scheie syndrome models
- Mechanism of action data to support a plausible biological link
- Health Canada package insert warnings and contraindications for safety screening
- Direct clinical or literature evidence in this disease before any further consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.